NCT lookup
Pull any trial record directly from ClinicalTrials.gov.
Safety and Immunogenicity of Pneumococcal Conjugate Formulations in Healthy Adults 18 Through 49 Years of Age
Safety and Immunogenicity of Pneumococcal Conjugate Formulations in Healthy Adults 18 Through 49 Years of Age
CompletedPhase 1
Sponsor: Pfizer
Conditions: Pneumococcal Disease
Interventions: Candidate-1, Candidate-2, Candidate-3, Candidate-4, Candidate-5
Countries: United States
The purpose of the study is to describe the safety and immunogenicity of Pneumococcal Conjugate Formulations in healthy adults 18 through 49 years of age.
Eligibility overview
Sex: ALL
Age: 18 Years to 49 Years
Healthy volunteers: Yes
Study type: INTERVENTIONAL
Eligibility criteria
Inclusion Criteria: * Male or female participants ≥18 and ≤49 years of age at the time of consent * Adults determined by clinical assessment to be eligible for the study, including adults with preexisting stable disease within 12 weeks before receipt of study intervention * Participants willing to use acceptable contraception for at least 28 days after study intervention; female participants not of childbearing potential; male participants unable to father children Exclusion Criteria: * History of severe adverse reaction associated with a vaccine and/or severe allergic reaction to any component in pneumococcal conjugate vaccines and any other diphtheria toxoid-containing vaccine * Serious chronic disorder that in the investigator's opinion would make the participant inappropriate for entry into the study * Medical or psychiatric condition (recent or active suicidal ideation/behavior or laboratory abnormality) that may increase risk of study participation or make participant inappropriate for the study * Known or suspected immunodeficiency or other conditions associated with immunosuppression * Previous vaccination with any licensed or investigational pneumococcal vaccine, or planned receipt of any licensed or investigational pneumococcal vaccine through study participation * Receipt of any inactivated or otherwise nonlive vaccine within 14 days or any live vaccine within 28 days before administration of study intervention
Locations (18)
- Tustin, California, United States
- Walnut Creek, California, United States
- Milford, Connecticut, United States
- Fort Lauderdale, Florida, United States
- Hialeah, Florida, United States
- South Miami, Florida, United States
- Elkridge, Maryland, United States
- Troy, Michigan, United States
- Saint Paul, Minnesota, United States
- Somers Point, New Jersey, United States
- Wilmington, North Carolina, United States
- San Antonio, Texas, United States
- San Antonio, Texas, United States
- San Antonio, Texas, United States
- Tomball, Texas, United States
- Salt Lake City, Utah, United States
- Salt Lake City, Utah, United States
- Norfolk, Virginia, United States